Astellas Pharmaceuticals Co. Ltd.
Astellas is No.2 in Japan and ranked number 20 worldwide with net sales of ¥ 1,348 Billion ($ 12 billion) in 2015.

It has a solid reputation as a leader in research based medicine as Astellas has research and development units at over 15 locations all around the world, including North America, Europe and Asia; Astellas is investing around ¥ 165 billion ($ 1.46 billion) in 2015.

The company’s R&D activities are focused on endocrinology, bone related disorders, and disease affecting the urogenital organs, central nervous system, circulatory system and digestive organs.

Astellas`s OMNIC ocas ‘‘tamsulosin” for example is being marketed in 65 countries around the world and is held No.1 position in its class in a lot of countries, including Saudi Arabia.
Astellas is committed to enforce the Urology and other pipelines with several new products which will be available in many regions through SAJA.

Contact Us

You can send us an email and we'll get back to you as soon as possible

Start typing and press Enter to search